ReviewBMC nephrology2026
Impaired fatty acid metabolism in AKI: experimental evidence - a narrative review.
Review in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a common and serious complication of hospitalized patients worldwide. In most cases, the syndrome is characterized by dysfunction/structural damage of the tubular epithelial cells. The metabolic feature is a reduction in cellular adenosine triphosphate (ATP) synthesis as a result of decreased fatty acid oxidation. Stabilization of the fatty acid (FA) oxidation process may influence the course of AKI, whether caused by endogenous or exogenous factors. In this narrative review, we discuss experimental evidence on the modulation of fatty acid metabolism in AKI.
methodsNarrative review article. The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 2010 until May 2026.
resultsFinally, 16 articles on the modulation of fatty acid metabolism in experimental AKI were identified. Disturbances in the FA oxidation process are associated with an aggravation of renal dysfunction in AKI, and lipids accumulate in the renal tissue itself. The consequences of exogenous fatty acid intake depend on the structural characteristics of the metabolites applied, as well as on the pattern of renal damage and the relevant pathophysiological processes.
conclusionsUnder certain conditions, adequate fatty acid oxidation may be considered nephroprotective; however, the complexity of the syndrome's pathophysiology must always be taken into account. Distinct fatty acids have the potential to offer therapeutic benefits in AKI cases. However, the efficacy of an FA-based therapeutic approach depends on two main factors: the chemical structure of the substances used and the nature of the underlying kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.